Division of Pediatric Neurology, University of Washington, Seattle Children's Hospital, Center for Integrative Brain Research, Seattle, WA, USA.
Headache. 2012 Oct;52(9):1377-86. doi: 10.1111/j.1526-4610.2012.02215.x. Epub 2012 Jul 13.
The goal of this study was to measure the effect of biofeedback therapy on pediatric headache and to identify factors associated with response to biofeedback therapy.
In the United States, 17% of children have frequent or severe headaches. Biofeedback therapy (BFT) appears to be an effective treatment for headaches in adults and is often recommended for children with headaches, but there are few data in the pediatric population. It is also not clear which patients are most likely to benefit from biofeedback therapy.
We examined the records of patients, aged 8 to 18 years old, who were referred to a pediatric BFT clinic for management of headache between 2004 and 2008. We extracted data regarding patient and headache characteristics, medication use, family history, and measures of depression, anxiety, and somatization. Chronic headache was defined as ≥4 headache days/week. Positive response to biofeedback was defined as a 50% reduction in number of headache days/week or hours/week, or ≥3-point decrease in severity (0-10 scale) between first and last visits. We analyzed the responder rate for those with episodic and chronic headaches and performed multivariable analysis to determine what factors were associated with headache response to biofeedback therapy.
We analyzed records from 132 children who attended ≥2 biofeedback sessions. Median headache frequency dropped from 3.5 to 2 headache days/week between the first and last visits. The response rate was 58% overall; 48% for chronic headaches and 73% episodic headaches. In multivariate analysis, ability to raise hand temperature by >3°F at the last visit and use of selective serotonin reuptake inhibitors (SSRIs) were associated with a positive response, and preventive medication use was associated with nonresponse. Anxiety, depression, and somatization were not significantly associated with response to biofeedback therapy.
Biofeedback therapy appears to be an effective treatment for children and adolescents with both episodic and chronic headaches. Further study is warranted to compare biofeedback with other treatments for chronic pediatric headache. Use of SSRIs appears to be associated with a positive response to biofeedback therapy, but the reasons for this relationship are unclear and merit further study.
本研究旨在评估生物反馈疗法对小儿头痛的疗效,并确定与生物反馈疗法疗效相关的因素。
在美国,17%的儿童经常或严重头痛。生物反馈疗法(BFT)似乎是成人头痛的有效治疗方法,常被推荐用于头痛的儿童,但在儿科人群中数据较少。也不清楚哪些患者最有可能从生物反馈治疗中受益。
我们检查了 2004 年至 2008 年间因头痛而被转介至儿科生物反馈治疗诊所的 8 至 18 岁患者的病历。我们提取了患者和头痛特征、药物使用、家族史以及抑郁、焦虑和躯体化的测量数据。慢性头痛定义为≥4 天/周头痛。生物反馈治疗的阳性反应定义为每周头痛天数/小时减少 50%,或在首次和最后就诊时严重程度(0-10 级)降低≥3 分。我们分析了发作性和慢性头痛患者的反应率,并进行了多变量分析,以确定哪些因素与生物反馈治疗对头痛的反应相关。
我们分析了≥2 次生物反馈治疗的 132 名儿童的记录。中位数头痛频率从首次就诊时的 3.5 天/周降至最后一次就诊时的 2 天/周。总体反应率为 58%;慢性头痛为 48%,发作性头痛为 73%。在多变量分析中,末次就诊时手温升高>3°F 的能力和使用选择性 5-羟色胺再摄取抑制剂(SSRIs)与阳性反应相关,而预防性药物使用与无反应相关。焦虑、抑郁和躯体化与生物反馈治疗的反应无显著相关性。
生物反馈疗法似乎是治疗儿童和青少年发作性和慢性头痛的有效方法。有必要进一步研究生物反馈与慢性儿科头痛的其他治疗方法的比较。SSRIs 的使用似乎与生物反馈治疗的阳性反应相关,但这种关系的原因尚不清楚,值得进一步研究。